Wire · opportunities
Legend Biotech taps Novartis veteran Zhang as CEO
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 16 September 2026 · Fusion42 review
Legend Biotech appointed Novartis veteran Ingrid Zhang as CEO to lead its expansion beyond the blockbuster cancer therapy Carvykti. The company continues development of advanced cell therapies and operates globally including the U.S. and China.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 15 Sep 2026 and 16 Sep 2026.
◆ ◆ The Wire takeaway
Biotech founders in cell therapy should watch Zhang’s move as it signals fresh strategic drive at Legend Biotech which could open new partnership or competitor threats in cancer treatment. You need to reassess your market positioning against a company renewing its leadership with a top commercial executive.
◆ Coverage
3 sources · first reported 15 Sep 2026 · latest 16 Sep 2026
◆ Related on Wire
◆ Topics